QNRX

QNRX

Quoin Pharmaceuticals Ltd DRC

Quoin Pharmaceuticals develops therapeutic products for rare and orphan diseases. Its lead product, QRX003, is a topical lotion for Netherton syndrome, while QRX008 targets scleroderma and QRX009 addresses various malformations, all in various development stages.

โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth-7.42%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth20.90%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Score
Net Growth-210.84%
Net Trend30%
Net Income Consistency
Rev Growth100.00%
Rev Trend13%
Revenue Consistency
All Time
Score
Net Growth-210.84%
Net Trend30%
Net Income Consistency
Rev Growth100.00%
Rev Trend13%
Revenue Consistency

See the full market ranking โ†’

Quoin Pharmaceuticals Ltd DRC fundamental performance

Between 2016 and 2025, revenue went from -$ 280K to $ 0.00 and net income went from $ 15M to -$ 15M. Revenue increased in 13% of the years measured; net income in 30%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 5.89โ€”
1 Year2025-08-12
$ 7.18-17.97%
5 Years2021-08-12
$ 83.79K-99.99%
10 Years2016-08-12
$ 544.95K-100.00%
All Time2016-07-29
$ 5.0017.92%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 16M$ 3M
2025$ 0.00-$ 15M$ 3.81B
2024$ 0.00-$ 8M$ 14M
2023$ 0.00-$ 8M$ 10M
2022$ 0.00-$ 9M$ 12M
2021$ 0.00-$ 21M$ 7M
2020$ 0.00-$ 2M$ 323.83K
2019$ 0.00-$ 1M$ 5M
2018-$ 280K$ 15M$ 4M
2017$ 10M$ 7M
IPO2016-$ 280K$ 15M$ 8M

Explore beyond QNRX

You're looking at Quoin Pharmaceuticals Ltd DRC. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies